Fig. 6.

Sustained peripheral depletion of CD8⁺ T cells following WBI-enhanced ACT does not promote tumor recurrence or eliminate donor T cells from the brain. WBI-conditioned mice received ACT with TCR-IV T cells. Beginning on day +20, groups of mice received weekly injections of control antibody or depleting anti-CD8. a Quantification of tetramer-IV⁺ T cells on day +80 in spleen and cLN. b The cross-sectional area of the largest lesion in each brain was calculated and plotted. n = 6 mice/group. c Immunohistochemical staining for SV40 T antigen on brain sections from mice in part b. d In a second experiment using CD90.1⁺ TCR-IV T cells, mice were harvested at day +80 post-ACT and CD90.1⁺ T cells were quantified in all three tissues. n = 4 mice/group. **p < 0.01; ***p < 0.001; ns not significant